Navidea Biopharmaceuticals Inc (NAVB) Return on Assets ROA from the third quarter of 2023 to third quarter of 2022 and for the year 2023, Average High and Low, Fundamental Ratios from Sep 30 2023 to Sep 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Navidea Biopharmaceuticals Inc   (NAVB)


Navidea Biopharmaceuticals Inc 's ROA from the third quarter of 2023 to the third quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Navidea Biopharmaceuticals Inc 's ROA in the third quarter of 2023?
Navidea Biopharmaceuticals Inc recorded a cumulative net loss of $-1 million during 12 months ending in the third quarter of 2023, resulting in a negative return on assets (ROA) of -22.9%.

However, within the Healthcare sector 398 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2023 quarter, so far to 3937, from total ROA ranking in the second quarter of 2023 at 4943.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter
Y / Y Total Assets Change -8.94 % 228.3 % -34.27 % -34.21 % -30.15 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -1 -5 -14 -15 -15
Return On Assets (TTM) -22.9 % -87.38 % -352.64 % -362.74 % -322.93 %
NAVB's Total Ranking # 3937 # 4943 # 5540 # 6353 # 5588
Total Assets (TTM) in million 6 8 2 4 6
Seq. Total Assets Change -30.67 % 247.18 % -45.84 % -30.15 % 149.96 %
Seq. Net Income Change - - - - -

NAVB's 5 Years Annual ROA >> Back to NAVB Management Effectiveness >> Compare NAVB ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 5
Sector # 399
Overall # 3871

Return On Assets Statistics
High Average Low
459.45 %
-118.28 %
-362.75 %
(Mar 31 2017)   (Dec 31 2022)





Financial Statements
Navidea Biopharmaceuticals Inc 's Assets $ 6 million NAVB's Balance sheet
Navidea Biopharmaceuticals Inc 's Income $ -2 million Quarterly NAVB's Income Statement
NAVB's Income by Division See NAVB's Income by Division



Annual Return On Assets (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020		 (Dec 31 2019)
FY 2019		 (Dec 31 2018)
FY 2018
Y / Y Total Assets Change -34.21 % -14.35 % 86.9 % -40.88 % -66.21 %
Total Assets in million 4 7 8 4 7
Y / Y Net Income Change - - - - -
Net Income in million -15 -12 -11 -11 -16
Annual Return On Assets -347.17 % -176.54 % -138.2 % -263.76 % -229.5 %

NAVB's 5 Years Annual ROA >> Back to NAVB Management Effectiveness >> Compare NAVB ROA to its Competitors



More Return On Assets Ratios
NAVB's' Return on Assets at Yahoo Finance
In Vitro & In Vivo Diagnostic Substances Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NAVB's Roa Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NAVB's Competitors
Subscribers only: Roa for Navidea Biopharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for NAVB's Customers

You may also want to know
NAVB's Roi NAVB's Inventory Turnover Ratio NAVB's Growth Rates NAVB's Dividend Comparisons
NAVB's Profitability Ratios NAVB's Asset Turnover Ratio NAVB's Dividend Growth
NAVB's Roe NAVB's Valuation Ratios NAVB's Financial Strength Ratios NAVB's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2023, within Healthcare Sector ROA

Date modified: 2026-08-29T17:28:48+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.